Concepedia

Tess Schmalbach

TS

Statistics

Publications

13

Citations

504

H-Index

12

Active since

2004

Affiliations

Northwestern University(Current)

Yale University

Wellesley College

Infinity Pharmaceuticals (United States)

Tess Schmalbach is an author at Northwestern University specializing in medicine, pharmacology, and oncology.

Publications per year

2004–2018

13

Publications

13

Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor

Lynda C. Schneider, William R. Lumry, Arthur B. Vegh et al. · Journal of Allergy and Clinical Immunology · 2007 · 126 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +4

Acetyl‐coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double‐blind, crossover study

Kathryn Stiede, Wenyan Miao, Heather Blanchette et al. · Hepatology · 2017 · 115 citations · Full text

Medicine, Biochemistry, Pharmacology +17

A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer.

Donald Richards, Joe Stephenson, Brian M. Wolpin et al. · Journal of Clinical Oncology · 2012 · 42 citations

Medicine, Pharmacology, Pharmacotherapy +17

Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON™), an Investigational Synthetic Toll-like Receptor 9 Agonist

Alain Vicari, Tess Schmalbach, Julie Lekstrom-Himes et al. · Antiviral Therapy · 2007 · 39 citations · Full text

Life Sciences, Immunology, Pharmacology +15

Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.

Alain Vicari, Tess Schmalbach, Julie Lekstrom-Himes et al. · PubMed · 2007 · 39 citations

Life Sciences, Immunology, Pharmacology +13

1–5 of 13